Strep steps up in urinary tract infections

Apr 23, 2010

Research suggests pathogenic strains of Group B Streptococcus (GBS) are an under-recognised cause of urinary tract infections.

The bacteria are better known as a cause of infection in pregnant women with subsequent risks of preterm delivery and transmission to newborn infants often with devastating consequences.

Microbiologist Dr Glen Ulett, from the Griffith Institute for Health and Medical Research, said pathogenic strains of GBS have been shown to bind to the surface of human bladder cells as the initial step in the development of urinary tract infections.

"Affected cells appear to change their morphology and secrete significant amounts of interleukin, an inflammatory cytokine which activates the body's immune system."

He said the interleukin levels associated with GBS infection were significantly higher than those associated with , the cause of 90 per cent of urinary tract infections. The findings have appeared in the Journal of .

"The fact that GBS causes more inflammation than E. coli was the exact opposite to what we expected and supports the notion that GBS is unique and may cause disease at a lower bacterial count than is typical," Dr Ulett said.

He said because GBS is part of the normal microbial flora of the in about 40 per cent of healthy women, isolation of the bacteria in urine samples was often attributed to contamination of the sample rather than an possible indicator of disease.

"Because there are no clearly defined risk factors for GBS infection, the high prevalence of the bacteria, and the difficulties of diagnosis, we are probably often overlooking this organism as a cause of urinary tract infections."

Dr Ulett said a clinical study of over 34,000 patients published last year in collaboration with Westmead Hospital, University of Queensland and the University of Alabama, showed that non-typeable GBS serotypes were not associated with urinary tract infections as was previously thought.

"Importantly, we showed that GBS serotype III was the only serotype more commonly associated with urinary tract infections compared with other serotypes. This gives us a better understanding of the potential targets for vaccine development."

He said while a vaccine to protect women against GBS urinary tract infections may not be a priority on its own, it may be a spin-off benefit from the need to protect newborn infants against fulminating GBS infection through maternal vaccination.

Explore further: Molecular method classifies patients with polycythemia vera

More information:
Journal of Infectious Diseases 2010; 201:866-70.
Journal of Clinical Microbiology 2009; 47(7):2055-2060.

add to favorites email to friend print save as pdf

Related Stories

Progress made on group B streptococcus vaccine

Oct 30, 2009

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus ...

FDA OKs urinary infection injectable drug

Oct 18, 2007

The U.S. Food and Drug Administration announced approval Thursday of doripenem (Doribax) injections for the treatment of complex urinary tract infections.

Recommended for you

Guidelines presented for diagnosing focal liver lesions

6 hours ago

(HealthDay)—Focal liver lesions (FLLs) are mostly benign, and can be diagnosed based on knowledge of their presentation, associated clinical and laboratory features, and natural history, according to clinical ...

Factors tied to neck, back pain improvement identified

10 hours ago

(HealthDay)—Observational registry-based research can inform patients and physicians about prognosis for subacute or chronic neck or low back pain, according to a study published in the Aug. 1 issue of ...

User comments : 0